Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

bination of two oral antiviral molecules to treat hepatitis C virus (HCV) in the absence of interferon. The study will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor;

-- On January 11, 2009, Pharmasset announced that the company and its development partner, Roche, had agreed with the FDA on the design for a phase 2b trial with R7128, a nucleoside inhibitor of HCV, slated to initiate in the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset filed an IND for PSI-7851, a nucleotide inhibitor of HCV, with the FDA and expects to initiate a Phase 1 clinical trial to study safety and pharmacokinetics in healthy volunteers at the end of the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset and Bukwang Pharm. Co., Ltd. entered into an amendment of their license agreement covering clevudine. The amendment expands the territories in which Pharmasset has been granted rights to include Australia, Japan, New Zealand and Taiwan;

-- On February 5, 2009, Pharmasset completed a registered direct offering that raised net proceeds of $43.5 million.

"We had a very productive start to 2009, filing an IND for PSI-7851, our second generation nucleotide for HCV and, strengthening our balance sheet by raising $43.5 million in a tough financial market" stated Schaefer Price, President and Chief Executive Officer. "Our goal remains to build a leading franchise of nucleoside inhibitors for hepatitis C and B. Our plan is to provide updates throughout the year on all of our programs, including the first antiviral data on PSI-7851 in the second half of 2009."

Calendar Year 2009 Anticipated Milestones:

-- Roche initiates phase 2b study of R7128 in first quarter of 2009;

-- Complete enrollment of clevudine registration trials at end of first quarter of 2009;

-- Initiate
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
(Date:8/26/2014)... The 20 ambassadors representing the ALS Therapy Development ... following statement on Facebook today regarding the global Ice ... specifically for ALS research: , “Who would have thought ... raise all this awareness and funding toward ALS research! ... of the entire ALS community, would like to express ...
(Date:8/26/2014)... 26, 2014  ViveBio, LLC a leading provider ... and transportation, announced today that it has signed ... (LPS) of Knoxville, Tennessee ... the United States . ViveST is ... temperature dried biological specimen transport systems.  The technology ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... 21 CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... been accepted for presentation at the American,College of Cardiology ... Chicago, IL on March 29 - April 1, 2008., ... Activity in Isolated Rat Left Atrial,Appendage; Poster; Sunday, March ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the fourth quarter and year-end 2007,financial results ... Chief Executive Officer of the Company, will host the ... in a press release to be,issued prior to the ...
... PDL BioPharma Have Entered into an Agreement Under, Which Genmab ... ... Minnesota, USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February ... PDLI ) announced today that they have entered into an ...
Cached Biology Technology:CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 2CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
(Date:8/25/2014)... biofuels industry: "You can make anything from lignin ... pave the way to challenging that adage. The ... Laboratory (NREL) demonstrates a concept that provides opportunities ... variety of renewable fuels, chemicals, and materials for ... Through Integrated Biological Funneling and Chemical Catalysis " ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... Researchers are still fascinated by the idea of the ... them into cells with the capacity to differentiate into ... are still striving to understand how it happens. ... (CNIO), headed by researcher Ralph P. Schneider, from the ...
... A new study finds that utilities aren,t rewarded for ... to make energy efficiency as attractive as renewables. ... Environmental Law , examines key differences between energy ... assistant professor at Oregon State University, outlines ways to ...
... a private company focused on the development of targeted ... has entered into a license agreement with the Spanish ... rights to develop and commercialise several novel kinase inhibitors ... CNIO,s considerable expertise in drug discovery and comprise a ...
Cached Biology News:CNIO researchers identify a new gene that is essential for nuclear reprogramming 2Study finds disincentives to energy efficiency can be fixed 2